İlaç salınımlı stentler diyabetik hastalarda koroner arter hastalığının tedavisini değiştirdi mi?

Diyabetik koroner arter hastalığı diffüz ve çok sayıda damar tutulumu, ince damar yapısı ve ilerleyici olması ile karakterizedir. Bu tip koroner arter hastalığında, diyabetik olmayan koroner arter hastalığı ile karşılaştırıldığında yeniden daralma oranları yüksektir. Son beş yılda ilaç salınımlı stentler perkütan koroner girişimlerin en önemli sorunu olan yeniden darlık konusunda oldukça umut verici sonuçlar elde edilmesini sağlamıştır. Bu bulgulara karşın, gerçek hayatta birçok diyabetik hasta, lezyon özellikleri ve iyi uzun dönem sonuçlar nedeniyle hala bypassa daha uygundur.

Have drug-eluting stents changed the management of coronary artery disease in diabetic patients?

Diabetic coronary artery disease is characterized by diffuse multivessel disease, small coronary arteries, and progressive nature. This type of coronary artery disease is also associated with high rates of restenosis compared to nondiabetic coronary artery disease. During the past five years drugeluting stents have provided promising results for preventing restenosis, which is currently the most important problem of percutaneous coronary interventions. However, in real life practice, bypass surgery is still more convenient for the majority of diabetic patients due to lesion characteristics and better long-term results.

PDF

___

1) Sicree R, Shaw JE, Zimmet PZ. The global burden of diabetes. In: Gan D, editor. Diabetes atlas. 2nd ed. Brussels: International Diabetes Federation; 2003. p. 15-71.
2) Mak KH, Faxon DP. Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J 2003; 24:1087-103.
3) Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014-9.
4) Chaour M, Theroux P, Gilfix BM, Campeau L, Lesperance J, Ghitescu M, et al. ‘True' fasting serum insulin level, insulin resistance syndrome and coronary artery disease. Coron Artery Dis 1997;8:683-8.
5) Melidonis A, Dimopoulos V, Lempidakis E, Hatzissavas J, Kouvaras G, Stefanidis A, et al. Angiographic study of coronary artery disease in diabetic patients in comparison with nondiabetic patients. Angiology 1999;50:997-1006.
6) Natali A, Vichi S, Landi P, Severi S, L'Abbate A, Ferrannini E. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome. Diabetologia 2000;43:632-41.
7) Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980;69:498-506.
8) Abaci A, Oğuzhan A, Kahraman S, Eryol NK, Unal S, Arinç H, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-42.
9) Arad Y, Newstein D, Cadet F, Roth M, Guerci AD. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron- beam computed tomographic study. Arterioscler Thromb Vasc Biol 2001;21:2051-8.
10) Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device specific analysis of 7147 patients. Circulation 2001;104:642-7.
11) Singh M, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, et al. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005;45:198-203.
12) Van Belle E, Abolmaali K, Bauters C, McFadden EP, Lablanche JM, Bertrand ME. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol 1999;34:476 85.
13) Holmes DR Jr, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77C-81C.
14) Van Belle E, Bauters C, Hubert E, Bodart JC, Abolmaali K, Meurice T, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997;96:1454 60.
15) Van Belle E, Perie M, Braune D, Chmait A, Meurice T, Abolmaali K, et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 2002;40:410-7.
16) Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
17) Savage MP, Fischman DL, Rake R, Leon MB, Schatz RA, Penn I, et al. Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators. J Am Coll Cardiol 1998;31:307-11.
18) Kastrati A, Schomig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, et al. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 2000;102:2593-8.
19) Kereiakes DJ, Young JJ. Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents. Rev Cardiovasc Med 2005;6 Suppl 1:S48-58.
20) Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001;104:533-88.
21) Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004;109:1114-20.
22) Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005;46:575-81.
23) Shah PJ, Durairaj M, Gordon I, Fuller J, Rosalion A, Seevanayagam S, et al. Factors affecting patency of internal thoracic artery graft: clinical and angiographic study in 1434 symptomatic patients operated between 1982 and 2002. Eur J Cardiothorac Surg 2004;26:118-24.
24) Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-8.
25) Guagliumi G, Sousa E, Urban P. Sirolimus-eluting stent in routine clinical practice: a 6-month follow-up report from the international e-CYPHER registry. Circulation 2003;108(Suppl IV):IV-534. [Abstract]
26) Abizaid A. Sirolimus eluting stents in diabetic patients: Integrated analyis of six multicenter trials. In: The American College of Cardiology 2005. 54th Annual Scientific Session; March 6-9, 2005; Orlando, USA.
27) Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez- Hospital JA, Alfonso F, Hernandez-Antolin R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-83.
28) Abizaid A, Chan C, Kaul U. “Real world” evaluation of slowrelease, polymer based, paclitaxel-eluting Taxus stents in native coronary arteries, the WISDOM international registry. Circulation 2003;108(Suppl IV):IV-534. [Abstract]
29) Lasala J, and ARRIVE participating physicians. ARRIVE registry: a consecutive enrolling of drug eluting stent registry. Main session: Post market registries: a wealth of real life data. Euro PCR, 2005.
30) Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al. Outcomes with the polymer-based paclitaxeleluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-9.
31) Stone GW. The results of a meta-analysis of the TAXUS II, IV, V, and VI trials. In: The American College of Cardiology 2005. 54th Annual Scientific Session; March 6-9 2005; Orlando, USA.
32) Scheen AJ, Warzee F, Legrand VM. Drug-eluting stents: metaanalysis in diabetic patients. Eur Heart J 2004;25:2167-8.
33) Serruys PW, Lemos PA, van Hout BA. Arterial Revascularisation Therapies Study part II Steering Committee and Investigators. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart 2004;90:995-8.
34) Rodriguez A, Maree AO, Grinfeld L, Fernandez-Pereira C, Mieres J, Rodriguez Alemparte M, et al. Revascularization strategies of coronary multiple vessel disease in drug eluting stent era: one year follow up results of the ERACI III trial. EuroInterv 2006;2:53-60.
35) Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimuseluting stents with bare-metal stents. N Engl J Med 2007;356: 1030-9.
36) Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
37) Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
38) Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-402.
39) Future revascularization evaluation in patients with diabetes mellitus: optimal management of multivessel disease (FREEDOM). Available from: http://clinicaltrials.gov/ct/show/ NCT00086450.
40) Kapur A, Malik IS, Bagger JP, Anderson JR, Kooner JS, Thomas M, et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J 2005;149:13-9.
41) Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, et al. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006;97:9G-19G.
42) Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47